Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

The Stability of Comorbid Psychiatric Disorders: A 7 Year Follow Up of Children with Pervasive Developmental Disorder-Not Otherwise Specified.

Verheij C, Louwerse A, van der Ende J, Eussen ML, Van Gool AR, Verheij F, Verhulst FC, Greaves-Lord K.

J Autism Dev Disord. 2015 Dec;45(12):3939-48. doi: 10.1007/s10803-015-2592-5.

2.

ASD Symptom Severity in Adolescence of Individuals Diagnosed with PDD-NOS in Childhood: Stability and the Relation with Psychiatric Comorbidity and Societal Participation.

Louwerse A, Eussen ML, Van der Ende J, de Nijs PF, Van Gool AR, Dekker LP, Verheij C, Verheij F, Verhulst FC, Greaves-Lord K.

J Autism Dev Disord. 2015 Dec;45(12):3908-18. doi: 10.1007/s10803-015-2595-2.

3.

Preoperative chemoradiotherapy for esophageal or junctional cancer.

van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, Richel DJ, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, Spillenaar Bilgen EJ, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW, van der Gaast A; CROSS Group.

N Engl J Med. 2012 May 31;366(22):2074-84. doi: 10.1056/NEJMoa1112088.

4.

Pathology practice patterns affect lymph node evaluation and outcome of colon cancer: a population-based study.

Lemmens VE, van Lijnschoten I, Janssen-Heijnen ML, Rutten HJ, Verheij CD, Coebergh JW.

Ann Oncol. 2006 Dec;17(12):1803-9. Epub 2006 Sep 13.

PMID:
16971667
5.

Greater influence of age than co-morbidity on primary treatment and complications of prostate cancer patients: an in-depth population-based study.

Houterman S, Janssen-Heijnen ML, Verheij CD, Kil PJ, van den Berg HA, Coebergh JW.

Prostate Cancer Prostatic Dis. 2006;9(2):179-84. Epub 2006 Mar 14.

PMID:
16534509
6.

Mixed adherence to clinical practice guidelines for colorectal cancer in the Southern Netherlands in 2002.

Lemmens VE, Verheij CD, Janssen-Heijnen ML, Rutten HJ, Coebergh JW; Gastro-Intestinal Cancer Study Group Comprehensive Cancer Centre South IKZ, Eindhoven, The Netherlands.

Eur J Surg Oncol. 2006 Mar;32(2):168-73. Epub 2006 Jan 4.

PMID:
16387468
7.

[The correlation of age and comorbidity with therapy and survival in cancer patients in North-Brabant and North-Limburg, 1995-2001].

Janssen-Heijnen ML, Maas HA, Lemmens VE, Houterman S, Louwman WJ, Verheij CD, Coebergh JW.

Ned Tijdschr Geneeskd. 2005 Jul 23;149(30):1686-90. Dutch.

PMID:
16104115
8.

Co-morbidity leads to altered treatment and worse survival of elderly patients with colorectal cancer.

Lemmens VE, Janssen-Heijnen ML, Verheij CD, Houterman S, Repelaer van Driel OJ, Coebergh JW.

Br J Surg. 2005 May;92(5):615-23.

PMID:
15779071
9.

A phase I and pharmacologic study of the matrix metalloproteinase inhibitor CP-471,358 in patients with advanced solid tumors.

Planting A, van der Gaast A, Schöffski P, Bartkowski M, Verheij C, Noe D, Ferrante K, Verweij J.

Cancer Chemother Pharmacol. 2005 Feb;55(2):136-42. Epub 2004 Sep 29.

PMID:
15592721
10.
11.

Phase I and pharmacokinetic study of XR11576, an oral topoisomerase I and II inhibitor, administered on days 1-5 of a 3-weekly cycle in patients with advanced solid tumours.

de Jonge MJ, Kaye S, Verweij J, Brock C, Reade S, Scurr M, van Doorn L, Verheij C, Loos W, Brindley C, Mistry P, Cooper M, Judson I.

Br J Cancer. 2004 Oct 18;91(8):1459-65.

12.

Anaemia prior to operation is related with poorer long-term survival in patients with operable rectal cancer.

van Halteren HK, Houterman S, Verheij CD, Lemmens VE, Coebergh JW.

Eur J Surg Oncol. 2004 Aug;30(6):628-32.

PMID:
15256236
13.

Comorbidity has negligible impact on treatment and complications but influences survival in breast cancer patients.

Houterman S, Janssen-Heijnen ML, Verheij CD, Louwman WJ, Vreugdenhil G, van der Sangen MJ, Coebergh JW.

Br J Cancer. 2004 Jun 14;90(12):2332-7.

14.

Phase I and pharmacokinetic study of irinotecan in combination with R115777, a farnesyl protein transferase inhibitor.

Sparreboom A, Kehrer DF, Mathijssen RH, Xie R, de Jonge MJ, de Bruijn P, Planting AS, Eskens FA, Verheij C, de Heus G, Klaren A, Zhang S, Verhaeghe T, Palmer PA, Verweij J.

Br J Cancer. 2004 Apr 19;90(8):1508-15.

15.

Phase I and pharmacological study of increased dose oral topotecan in combination with intravenous cisplatin.

Gelderblom AJ, Loos WJ, de Jonge MJ, Sparreboom A, Planting AS, van der Burg ME, Brouwer E, Verheij C, Ouwens L, Hearn S, Verweij J.

Ann Oncol. 2000 Sep;11(9):1205-7. No abstract available.

PMID:
11061621
16.

Variable FMR1 gene methylation of large expansions leads to variable phenotype in three males from one fragile X family.

de Vries BB, Jansen CC, Duits AA, Verheij C, Willemsen R, van Hemel JO, van den Ouweland AM, Niermeijer MF, Oostra BA, Halley DJ.

J Med Genet. 1996 Dec;33(12):1007-10. Review.

17.

FMRP is associated to the ribosomes via RNA.

Tamanini F, Meijer N, Verheij C, Willems PJ, Galjaard H, Oostra BA, Hoogeveen AT.

Hum Mol Genet. 1996 Jun;5(6):809-13.

PMID:
8776596
18.

Normal phenotype in two brothers with a full FMR1 mutation.

Smeets HJ, Smits AP, Verheij CE, Theelen JP, Willemsen R, van de Burgt I, Hoogeveen AT, Oosterwijk JC, Oostra BA.

Hum Mol Genet. 1995 Nov;4(11):2103-8.

PMID:
8589687
19.

Characterization of FMR1 proteins isolated from different tissues.

Verheij C, de Graaff E, Bakker CE, Willemsen R, Willems PJ, Meijer N, Galjaard H, Reuser AJ, Oostra BA, Hoogeveen AT.

Hum Mol Genet. 1995 May;4(5):895-901.

PMID:
7633450
20.

Characterization and localization of the FMR-1 gene product associated with fragile X syndrome.

Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R, Verkerk AJ, Galjaard H, Reuser AJ, Hoogeveen AT, Oostra BA.

Nature. 1993 Jun 24;363(6431):722-4.

PMID:
8515814

Supplemental Content

Loading ...
Support Center